{"t":"DOCUMENT","c":"","l":0,"ch":[{"t":"CONTAINER","c":"html","l":1,"ch":[{"t":"CONTAINER","c":"head","l":2,"ch":[{"t":"CONTAINER","c":"title","l":3},{"t":"CONTAINER","c":"meta","l":3}]},{"t":"CONTAINER","c":"body","l":2,"ch":[{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"ix:header","l":4,"ch":[{"t":"CONTAINER","c":"ix:hidden","l":5,"ch":[{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"false","l":7}]},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"--12-31","l":7}]},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"0001757499","l":7}]}]},{"t":"CONTAINER","c":"ix:references","l":5,"ch":[{"t":"CONTAINER","c":"link:schemaref","l":6}]},{"t":"CONTAINER","c":"ix:resources","l":5,"ch":[{"t":"CONTAINER","c":"xbrli:context","l":6,"ch":[{"t":"CONTAINER","c":"xbrli:entity","l":7,"ch":[{"t":"CONTAINER","c":"xbrli:identifier","l":8,"ch":[{"t":"SECTION_TITLE","c":"0001757499","l":9}]}]},{"t":"CONTAINER","c":"xbrli:period","l":7,"ch":[{"t":"CONTAINER","c":"xbrli:startdate","l":8,"ch":[{"t":"SECTION_TITLE","c":"2024-08-05","l":9}]},{"t":"CONTAINER","c":"xbrli:enddate","l":8,"ch":[{"t":"SECTION_TITLE","c":"2024-08-05","l":9}]}]}]},{"t":"CONTAINER","c":"xbrli:unit","l":6,"ch":[{"t":"CONTAINER","c":"xbrli:measure","l":7,"ch":[{"t":"SECTION_TITLE","c":"iso4217:USD","l":8}]}]},{"t":"CONTAINER","c":"xbrli:unit","l":6,"ch":[{"t":"CONTAINER","c":"xbrli:measure","l":7,"ch":[{"t":"SECTION_TITLE","c":"xbrli:shares","l":8}]}]},{"t":"CONTAINER","c":"xbrli:unit","l":6,"ch":[{"t":"CONTAINER","c":"xbrli:divide","l":7,"ch":[{"t":"CONTAINER","c":"xbrli:unitnumerator","l":8,"ch":[{"t":"CONTAINER","c":"xbrli:measure","l":9,"ch":[{"t":"SECTION_TITLE","c":"iso4217:USD","l":10}]}]},{"t":"CONTAINER","c":"xbrli:unitdenominator","l":8,"ch":[{"t":"CONTAINER","c":"xbrli:measure","l":9,"ch":[{"t":"SECTION_TITLE","c":"xbrli:shares","l":10}]}]}]}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"UNITED\nSTATES","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"UNITED\nSTATES","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"UNITED\nSTATES","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"SECURITIES\nAND EXCHANGE COMMISSION","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"SECURITIES\nAND EXCHANGE COMMISSION","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"SECURITIES\nAND EXCHANGE COMMISSION","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Washington,\nD.C. 20549","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Washington,\nD.C. 20549","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Washington,\nD.C. 20549","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"b","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":8}]}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"CURRENT\nREPORT","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"CURRENT\nREPORT","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"CURRENT\nREPORT","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto Section 13 OR 15(d) of The Securities Exchange Act of 1934","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto Section 13 OR 15(d) of The Securities Exchange Act of 1934","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto Section 13 OR 15(d) of The Securities Exchange Act of 1934","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"August 5, 2024","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"August 5, 2024","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"SHUTTLE\nPHARMACEUTICALS HOLDINGS, INC.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"SHUTTLE\nPHARMACEUTICALS HOLDINGS, INC.","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"SHUTTLE\nPHARMACEUTICALS HOLDINGS, INC.","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"SHUTTLE\nPHARMACEUTICALS HOLDINGS, INC.","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"SHUTTLE\nPHARMACEUTICALS HOLDINGS, INC.","l":8}]}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"(Exact\nname of registrant as specified in its charter)","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"(Exact\nname of registrant as specified in its charter)","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Delaware","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"001-41488","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"82-5089826","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"(State\n    or other jurisdictionof incorporation)","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"CommissionFile Number","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"(IRS\n    EmployerIdentification No.)","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"401\nProfessional Drive","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"401\nProfessional Drive","l":7}]}]},{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"Suite 260","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"Suite 260","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"Gaithersburg","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"Gaithersburg","l":7}]}]},{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"MD","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"MD","l":7}]}]},{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"20879","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"20879","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"(Address\nof principal executive offices) (Zip Code)","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"(Address\nof principal executive offices) (Zip Code)","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"(240)","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"(240)","l":7}]}]},{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"430-4212","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"430-4212","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"(Registrant’s\ntelephone number, including area code)","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"(Registrant’s\ntelephone number, including area code)","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"☐","l":6},{"t":"TABLE_CELL","c":"Written\n    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"☐","l":6},{"t":"TABLE_CELL","c":"Soliciting\n    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"☐","l":6},{"t":"TABLE_CELL","c":"Pre-commencement\n    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"☐","l":6},{"t":"TABLE_CELL","c":"Pre-commencement\n    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Securities\nregistered pursuant to Section 12(b) of the Act:","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Securities\nregistered pursuant to Section 12(b) of the Act:","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Title\n    of each class","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Trading\n    Symbol(s)","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Name\n    of each exchange on which registered","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Common\n    Stock $0.00001 per share","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"SHPH","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"The\n    Nasdaq Stock Market LLC","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Indicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Indicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"☒","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"☒","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"☐","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"☐","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"","l":7}]}]}]}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Item 1.01 Entry into a Material Definitive Agreement.","l":4},{"t":"CONTAINER","c":"b","l":4,"ch":[{"t":"SECTION_TITLE","c":"Item 1.01 Entry into a Material Definitive Agreement.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"On August\n6, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an amendment agreement\n(the “Amendment Agreement”) for purposes of amending the terms of the Securities Purchase Agreement, originally dated January\n11, 2023 (the “SPA”), between the Company, Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B (“Alto”),\nin its capacity as the registered holder of a $4.3 million convertible note (the “Alto Note”) and warrant to purchase 1,018,079\nshares of common stock (the “Alto Warrant”) issued by the Company and the Company’s wholly owned subsidiary, Shuttle\nPharmaceuticals, Inc., as guarantor.","l":4}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Under the\nAmendment Agreement, the Company and Alto agreed as follows: (i) that the Company would pay $600,000 (the “Cash Collateral”)\nin cash by wire transfer of immediately available funds to Alto, which would be held as collateral on the remaining $1.2 million outstanding\nunder the Alto Note; (ii) Alto will defer the monthly installment payment due on September 3, 2024 under the Alto Note until the Alto\nNote’s March 11, 2025 maturity date; and (iii) Alto would grant a waiver of any default Section 4(a)(xvi) of the Note related to\nthe restatement and reaudit of the Company’s financial statements for the years ended December 31, 2022 and 2023 (the “Reaudit”).\nThe Reaudit occurred due to certain errors in the Company’s 2022 financial statements and will require the Company to file an amended\nAnnual Report on Form 10-K/A for the period ended December 31, 2023 (the “Form 10-K/A”) and an amended Quarterly Report on\nForm 10-Q/A for the period ended March 31, 2024. On August 6, 2024, the Company provided the $600,000 Cash Collateral to Alto.","l":4}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"The foregoing description of the\nAmendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which agreement\nis attached hereto as Exhibit 10.1 and incorporated herein by reference.","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Item\n3.03 Material Modification to Rights of Security Holders.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Item\n3.03 Material Modification to Rights of Security Holders.","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item\n3.03 Material Modification to Rights of Security Holders.","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"To\nthe extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item\n5.03 of this Current Report on Form 8-K is incorporated by reference herein.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"To\nthe extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item\n5.03 of this Current Report on Form 8-K is incorporated by reference herein.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Item\n5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Item\n5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item\n5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"the “Company”) held on July 31, 2024","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"one-for-eight\n(1:8)","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto such authority granted by the Company’s stockholders at the Annual Meeting, the Board approved a one-for-eight (1:8) reverse\nstock split (the “Reverse Stock Split”) of the Common Stock on August 5, 2024 and on August 6, 2024, the Company filed\na certificate of amendment to amend the certificate of incorporation of the Company (the “Certificate of Amendment”) with","l":5}]},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"the Secretary of State of the State of Delaware, with\nan effective date of August 13, 2024 (the “Effective Date”). The Reverse Stock Split will become effective at the start of\ntrading on August 13, 2024 (the “Effective Time”). When the Reverse Stock Split becomes effective, every eight (8) shares\nof the Company’s issued and outstanding Common Stock immediately prior to the Effective Time shall automatically be reclassified\ninto one (1) share of Common Stock, without any change in the par value per share. The Reverse Stock Split reduces the number of shares\nof Common Stock issuable upon the exercise or vesting of the Company’s outstanding warrants and restricted stock units in proportion\nto the ratio of the Reverse Stock Split and causes a proportionate increase in the exercise prices of such stock options. The Reverse\nStock Split did not change the total number of authorized shares of Common Stock or preferred stock.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"2","l":7}]}]}]}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"PARAGRAPH","c":"p","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"No\nfractional shares will be issued as a result of the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional\nshare in connection with the Reverse Stock Split will receive one full share of the post-Reverse Stock Split Common Stock\nin lieu of such fractional share.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"No\nfractional shares will be issued as a result of the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional\nshare in connection with the Reverse Stock Split will receive one full share of the post-Reverse Stock Split Common Stock\nin lieu of such fractional share.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"in “street name” (through\na broker, bank or other holder of record)","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Commencing\non August 13, 2024, trading of the Company’s Common Stock will continue on The Nasdaq Capital Market on a Reverse Stock Split-adjusted\nbasis. The new CUSIP number for the Company’s Common Stock following the Reverse Stock Split is 825693302.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Commencing\non August 13, 2024, trading of the Company’s Common Stock will continue on The Nasdaq Capital Market on a Reverse Stock Split-adjusted\nbasis. The new CUSIP number for the Company’s Common Stock following the Reverse Stock Split is 825693302.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"The\nforegoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to\nthe full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this report and incorporated by reference herein.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"The\nforegoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to\nthe full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this report and incorporated by reference herein.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Item 8.01 Other Events.","l":4},{"t":"CONTAINER","c":"b","l":4,"ch":[{"t":"SECTION_TITLE","c":"Item 8.01 Other Events.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"To the extent required by\nthis Item 8.01 of Form 8-K, the information regarding the Reaudit contained in Item 1.01 of this Current Report on Form 8-K is incorporated\nby reference herein. The Company intends to conduct an equity offering in the near term to fund its upcoming Phase 2 clinical trials,\nand will be filing a registration statement on Form S-1, as well as a shelf registration statement on Form S-3, as soon as it has filed\nits Annual Report on Form 10-K/A for the period ended December 31, 2023, its Form 10-Q/A for the period ended March 31, 2024, and its\nQuarterly Report on Form 10-Q for the period ended June 30, 2024.","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Item\n9.01 Financial Statements and Exhibits.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Item\n9.01 Financial Statements and Exhibits.","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item\n9.01 Financial Statements and Exhibits.","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"(d)\nExhibits","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"(d)\nExhibits","l":5},{"t":"CONTAINER","c":"i","l":5,"ch":[{"t":"SECTION_TITLE","c":"(d)\nExhibits","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Exhibit\n    No.","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Description","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"3.1","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Certificate\n    of Amendment of Shuttle Pharmaceuticals Holdings, Inc","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"10.1","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Amendment\n    Agreement, dated August 6, 2024, between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity\n    Master Fund, SPC – Segregated Master Portfolio B","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"104","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Cover\n    Page Interactive Data File (embedded within the inline XBRL document)","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"3","l":7}]}]}]}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"PARAGRAPH","c":"p","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"SIGNATURES","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"SIGNATURES","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"SIGNATURES","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"b","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Dated:","l":6},{"t":"TABLE_CELL","c":"August\n    7, 2024","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"SHUTTLE\n    PHARMACEUTICALS HOLDINGS, INC.","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"By:","l":6},{"t":"TABLE_CELL","c":"/s/\n    Timothy J. Lorber","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Name:","l":6},{"t":"TABLE_CELL","c":"Timothy\n    J. Lorber","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Title:","l":6},{"t":"TABLE_CELL","c":"Chief\n    Financial Officer","l":6},{"t":"TABLE_CELL","c":"","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"4","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]}]}]}]}